Cargando…

“A beacon of hope for relapsed multiple myeloma patients: TALVEY™”

Detalles Bibliográficos
Autores principales:	Khaliq, Nawal, Riaz, Rumaisa, Hasan, Aleeza, Alauddin, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536835/ https://www.ncbi.nlm.nih.gov/pubmed/37780814 http://dx.doi.org/10.1177/20363613231205749

Ejemplares similares

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

NORD. A beacon of hope for people with rare disorders
por: Putkowski, Stefanie
Publicado: (2010)

Lactate Dehydrogenase: The Beacon of Hope?
por: Pandarathodiyil, Anitha Krishnan, et al.
Publicado: (2022)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
por: Riaz, Rumaisa, et al.
Publicado: (2023)

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
por: Vincent, L, et al.
Publicado: (2015)

Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
por: Algahtani, Hussein, et al.
Publicado: (2023)

PARP inhibitors in gastric cancer: beacon of hope
por: Wang, Yali, et al.
Publicado: (2021)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
por: Cerchione, Claudio, et al.
Publicado: (2016)

Cellular immunotherapy as a beacon of hope for hematological malignancies
por: Lee, Hyun-Ju, et al.
Publicado: (2015)

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
por: Suzuki, K, et al.
Publicado: (2017)

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
por: Kim, Jin-Hyo, et al.
Publicado: (2022)

Extramedullary relapse of multiple myeloma presenting as massive upper gastrointestinal bleeding: a rare complication
por: Yasar, Bulent, et al.
Publicado: (2015)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

H-FABP: A beacon of hope for prediabetic heart disease
por: Ramesh, Priyamvadha, et al.
Publicado: (2020)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer
por: Tariq, Syed Maaz, et al.
Publicado: (2018)

Immortal time bias in retrospective analysis: comment on ‘Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma'
por: Hsieh, P-Y, et al.
Publicado: (2015)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
por: Pourabdollah, Maryam, et al.
Publicado: (2016)

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
por: Martin, Tom, et al.
Publicado: (2022)

Multiple Myeloma and Alkaline Phosphatase
por: Yavaşoğlu, İrfan, et al.
Publicado: (2015)

Re: Arcuri and Americo “Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis”
por: Davies, Faith E., et al.
Publicado: (2022)

Myeloma-associated amyloid arthropathy masquerading as seronegative arthritis
por: Garg, Akanksha, et al.
Publicado: (2020)

Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand
por: Niparuck, Pimjai, et al.
Publicado: (2010)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Carbamazepine and Multiple Myeloma: Possible Interaction
por: Günaldı, Meral, et al.
Publicado: (2013)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses
por: Yao, Qiumei, et al.
Publicado: (2018)

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
por: Ludwig, H, et al.
Publicado: (2017)

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
por: Baker, David, et al.
Publicado: (2021)

The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma
por: Elsabah, Hesham, et al.
Publicado: (2020)

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
por: Barbieri, Emiliano, et al.
Publicado: (2022)

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
por: Ozaki, S, et al.
Publicado: (2015)

Hemisection-hope for last survival
por: Hasija, Mukesh, et al.
Publicado: (2013)

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020)

A new hope for patients suffering from multiple myeloma
por: Yu, Jinhua, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_co0odakv5eomngoistd31hknj9